A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease

Peripheral Vascular Diseases Clinical Trial

Official title:

A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01183117
• Other study ID #: SM-01
• Status: Completed
• Phase: Phase 3
• First received: August 1, 2010
• Last updated: March 31, 2015
• Start date: July 2010
• Est. completion date: August 2014

Study information

• Verified date: March 2015
• Source: Johnson & Johnson K.K. Medical Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Pharmaceuticals and Medical Devices Agency
• Study type: Interventional

Clinical Trial Summary

The main objective is to evaluate the safety and efficacy of SM-01 stenting (Cordis S.M.A.R.T.™ Nitinol Stent System) for the treatment of SFA lesions as compared to PTA (balloon angioplasty). If SM-01 is used in a PTA-bailout patient, the case will be assessed separately.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 105
• Est. completion date: August 2014
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Age >= 20 years.

2. Symptomatic leg ischemia by Rutherford Classification (category1, 2, or 3).

3. Lesion length >= 40 mm to <= 150 mm. (must be treatable with no more than two SM-01 stents. Overlap should be about 1cm if two stents are used)

4. Reference vessel diameter (RVD) >= 4.0 mm and <= 7.0 mm.

5. All lesions are to be located >= 3.0 cm proximal to the superior edge of the patella, and >= 1.0 cm distal to the SFA / PFA bifurcation.

6. >= 50% stenosis or total occlusion.

7. Patent infrapopliteal and popliteal arteries, i.e., single-vessel runoff or better with at least one of three vessels patent (< 50% stenosis) to the ankle or foot.

8. Patient or legally authorized representative must provide written informed consent prior to initiation of study procedures.

9. A patient with bilateral obstructive SFA disease is eligible for enrollment into the study. If a patient with bilateral disease is enrolled, the target limb will be the more severe limb. The more severe limb will be selected according to clinical symptomatology. If clinical symptomatology is similar, the more clinically severe lesion will be selected. The contralateral procedure should not be done until at least 30 days after the index procedure of the more severe limb was attempted.

Exclusion Criteria:

1. Recent hemorrhagic disease within the past 3 months.

2. Aneurysm in the SFA or popliteal artery.

3. Acute limb occlusion.

4. Procedures which are pre-determined to require stent-in-stent placement to obtain patency, such as severe calcification which is resistant to stenting, or for in-stent restenosis.

5. Poor iliac or common femoral "inflow".(However, intervention to restore adequate blood flow prior to the treatment of the study lesion is allowed.)

6. Known allergies to aspirin, heparin, or ticlopidine, or bleeding diathesis.

7. Patients unable or unwilling to tolerate anticoagulant or antiplatelet therapy.

8. Patients unable or unwilling to tolerate contrast agents used in intravascular procedures.

9. Allergic to nitinol or tantalum.

10. Women who are pregnant or lactating, or of child bearing potential, or with a desire to be a parent during the study period.

11. Significant vessel tortuosity or other parameters prohibiting access to the lesion or which would prevent delivery of the stent device.

12. Revascularization involving the same limb 30 days prior to the index procedure or a planned re-vascularization within 30 days after the index procedure.

13. Previously implanted stent(s) at the same site in the artery to be treated.

14. Requiring stent placement in the distal SFA or popliteal artery.

15. Presence of a femoral artificial graft.

16. History of participating in any other clinical study within 1 year.

17. Life expectancy less than 3 years, or any other factors preventing clinical follow-up.

18. Receiving dialysis or immunosuppressant therapy

19. Serum creatinine level >= 2.0 mg/dL before procedure.

20. A principal investigator or a co-principal investigator determines that patient is unsuitable for this study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases
• Vascular Diseases

Intervention

Device:
• SM-01
SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
• PTA
balloon angioplasty

Locations

Country	Name	City	State
Japan	Toho University Ohashi Medical Center	Meguro-ku	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson K.K. Medical Company

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Non-TVF(Target-vessel failure) rate	The primary endpoint will be freedom from TVF defined as any events of clinical driven (confirmed by duplex ultrasound or angiography) TLR/TVR, procedure failure, amputation of the target lesion's leg, procedure or device related death, occlusion of target lesion, or > 70% restenosis of target lesion.	12 Months	Yes
Secondary	Procedure Success rate		12 Months	Yes
Secondary	Procedure Success rate for Bailout		12 Months	Yes
Secondary	Difference between pre and post proceduer of ABI		12 Months	Yes
Secondary	Difference between pre and post procedure of Rutherford Categories		12 Months	Yes
Secondary	Non-TLR/TVR rate		12 Months	Yes
Secondary	Primary Patency rate		12 Months	Yes
Secondary	Stent Fracture rate		12 Months	Yes
Secondary	Difference between pre and post procedure of QOL (SF-36)		12 Months	Yes
Secondary	Major Clinical Event rate		12 Months	Yes